Gastroprotective drugs in Australia: Utilization patterns between 1997 and 2006 in relation to NSAID prescribing

Clinical Therapeutics

Volumn 31, Issue 4, 2009, Pages 849-861

  Barozzi, Nadia ^a   Tett, Susan E ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

COX 2 inhibitors; H2 receptor antagonists; nonsteroidal anti inflammatory drugs; prescribing; proton pump inhibitors

Indexed keywords

CIMETIDINE; ESOMEPRAZOLE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; NIZATIDINE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE;

ARTICLE; AUSTRALIA; COST BENEFIT ANALYSIS; DATA ANALYSIS; DRUG CLASSIFICATION; DRUG COST; DRUG USE; DRUG UTILIZATION; FUNDING; GOVERNMENT; MEDICARE; PRESCRIPTION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; AUSTRALIA; CYCLOOXYGENASE 2 INHIBITORS; HEALTH EXPENDITURES; HISTAMINE H2 ANTAGONISTS; HUMANS; NATIONAL HEALTH PROGRAMS; PEPTIC ULCER; PHYSICIAN'S PRACTICE PATTERNS; PROTON PUMP INHIBITORS; REIMBURSEMENT MECHANISMS;

EID: 65549127109     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.04.012     Document Type: Article

References (62)

1. North of England Dyspepsia Guideline Development Group. Dyspepsia: Managing dyspepsia in adults in primary care 2004. http://www.nice.org.uk/nicemedia/pdf/CG017fullguideline.pdf Accessed January 1, 2009
2. The Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists, The Pharmaceutical Society of Australia, The Royal Australian College of General Practitioners. Australian Medicines Handbook 2007. http://amh.hcn.net.au/
3. Therapeutic Guidelines: Gastrointestinal Expert Group. Therapeutic Guidelines Gastrointestinal Version 4, 2006 (2006), Therapeutic Guidelines Ltd, Melbourne, Australia. http://www.tg.org.au/index.php?sectionid=45 Accessed March 12, 2009
4. Laine L. The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors. Semin Arthritis Rheum. 32 Suppl 1 (2002) 25-32
5. Ehsanullah R.S., Page M.C., Tildesley G., and Wood J.R. Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: Controlled trial of ranitidine. BMJ 297 (1988) 1017-1021
6. Hudson N., Taha A.S., Russell R.I., et al. Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration. Gastroenterology. 112 (1997) 1817-1822
7. Yeomans N.D., Tulassay Z., Juhász L., et al., the Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med. 338 (1998) 719-726
8. National Institute for Clinical Excellence. Guidance on the use of cyclo-oxygenase (COX) II selective inhibitors, cele-coxib, rofecoxib, meloxicam and etodolac for osteoarthri-tis and rheumatoid arthritis. http://www.nice.org.uk/nicemedia/pdf/coxiifullguidance.pdf Accessed January 1, 2009
9. Rostom A., Dube C., Wells G., et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev. (2002) CD002296
10. Furst D.E. Meloxicam: Selective COX-2 inhibition in clinical practice. Semin Arthritis Rheum. 26 Suppl 1 (1997) 21-27
11. Hawkey C., Kahan A., Steinbrück K., et al., the International MELISSA Study Group. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. Meloxicam Large-scale International Study Safety Assessment [published correction appears in Br J Rheumatol. 1998;37:1142]. Br J Rheumatol. 37 (1998) 937-945
12. Scheiman J.M. Outcomes studies of the gastrointestinal safety of cyclooxygenase-2 inhibitors. Cleve Clin J Med. 69 Suppl 1 (2001) SI40-SI46
13. Silverstein F.E., Faich G., Goldstein J.L., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284 (2000) 1247-1255
14. Barclay L. Vioxx withdrawal prompts reevaluation of COX-2 inhibitor safety. Medscape Medical News (2004). http://www.medscape.com/viewarticle/490979Psrc-mp Accessed March 12, 2009
15. Lanas A. Review article: Recommendations for the clinical management of patients taking non-steroidal anti-inflammatory drugs-a gastroenterologist's prospective. Aliment Pharmacol Ther. 1 (2005) 16-19
16. Barozzi N., and Tett S.E. What happened to the prescribing of other COX-2 inhibitors, paracetamol and non-steroidal anti-inflammatory drugs when rofe-coxib was withdrawn in Australia?. Pharmacoepidemiol Drug Saf. 16 (2007) 1184-1191
17. National Prescribing Service. Proton pump inhibitors: Too much of a good thing?. NPS News 2004:33. Sydney (2004), National Prescribing Service Limited, Australia. http://www.nps.org.au/__data/assets/pdf_file/0016/15820/news33.pdf Accessed March 12, 2009
18. Australian Government, Department of Health and Ageing. Pharmaceutical Pricing Section Pharmaceutical Benefits Branch. Expenditure and prescriptions: Twelve months to 31 December 2005. http://www.health.gov.au/internet/wcms/publishing.nsf/Content/1CF96D8028 AE509ECA2570BA001AC076/$File/complete.pdf Accessed October 9, 2007
19. Australian Department of Health and Aged Care. Australian Statistic on Medicines 1997. http://www.health.gov.au/internet/wcms/publishing.nsf/Content/health-pbs -general-pubs-asm.htm/$FILE/asm97.pdf Accessed October 25, 2007
20. World Health Organization. ATC index with DDDs (2006), Collaborating Centre for Drug Statistics Methodology, Oslo, Norway. http://www.ecosante.org/OCDEENG/720020.html Accessed March 12, 2009
21. Commonwealth Department of Health and Family Services. Australian Statistics on Medicines 1997. http://www.health.gov.au/internet/main/Publishing.nsf/Content/health-pbs -general-pubs-asm.htm/$FILE/asm97.pdf Accessed March 12, 2009
22. Brown L., Abello A., Phillips B., and Harding A. The Australian Pharmaceuticals Benefit Scheme and Older Australians: Changes in Government Outlays and Consumer Costs from the 2002-03 Federal Budget Measures. In: Gupta A., and Harding A. (Eds). Modelling Our Future: Population Ageing, Health, and Aged Care (2003), Elsevier, Boston, Mass 169-196
23. Nair B. Older people and medications: What is the right prescription?. Australian Prescriber. 22 (1999) 130-131
24. The University of Adelaide. Discipline of General Practice. Medic-GP: Overview 2007. http://www.adelaide.edu.au/health/gp/units/medic-gp/overview/ Accessed December 27, 2007
25. Australian General Practice Statistics and Classification Centre (AGPSCC). The BEACH project. Bettering the Evaluation and Care of Health. [AGPSCC Web site]. http://www.fmrc.org.au/beach.htm Accessed December 27, 2007
26. Gastroenterological Society of Australia. NSAID therapy-maximizing the benefit, minimizing the risk (2004). http://www.gesa.org.au/members_booklets/nsaid/NSAIDTherapy.pdf Accessed May 12
27. Bergman U., Popa C., Tomson Y., et al. Drug utilization 90%-a simple method for assessing the quality of drug prescribing. Eur J Clin Pharmacol. 54 (1998) 113-118
28. Use and misuse. WHO Collaborating Centre for Drug Statistics Methodology (WHOCC). http://www.whocc.no/atcddd/use_misuse.html Accessed March 12, 2009
29. National Prescribing Centre. Prescribing antiplatelet drugs in primary care. MeReC Bulletin. 15 (2004) 21-24
30. Creutzfeldt W. Chiral switch, a successful way to drug development: Example of esomeprazole [in German]. Z Gastroenterol. 38 (2000) 893-897
31. Angell M. The Truth About the Drug Companies: How They Deceive Us and What To Do About It (2006), Scribe Publications, Melbourne, Australia
32. Australian Government, and Department of Health and Ageing. Pharmaceutical Benefits Pricing Authority. Annual Reports. http://www.health.gov.au/internet/main/publishing.nsf/Content/health-pbs -general-pricing-pbparpt.htm Accessed March 12, 2009
33. Lindberg P., Keeling D., Fryklund J., et al. Review article: Esomeprazole-enhanced bioavailability, specificity for the proton pump and inhibition of acid secretion. Aliment Pharmacol Ther 17 (2003) 481-488
34. Castell D.O., Kahrilas P.J., Richter J.E., et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 97 (2002) 575-583
35. Richter J.E., Kahrilas P.J., Johanson J., et al., the Esomeprazole Study Investigators. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: A randomized controlled trial. Am J Gastroenterol 96 (2001) 656-665
36. Kahrilas P.J., Falk G.W., Johnson D.A., et al., the Esomeprazole Study Investigators. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: A randomized controlled trial. Aliment Pharmacol Ther 14 (2000) 1249-1258
37. McDonagh M.S., and Carson S. Drug class review on proton pump inhibitors. Updated final report (2004), Oregon Evidence-Based Practice Center, Portland, Ore
38. Soga T., Matsuura M., Kodama Y., et al. Is a proton pump inhibitor necessary for the treatment of lowergrade reflux esophagitis?. J Gastroenterol 34 (1999) 435-440
39. Rackoff A., Agrawal A., Hila A., et al. Histamine-2 receptor antagonists at night improve gastroesophageal reflux disease symptoms for patients on proton pump inhibitor therapy. Dis Esophagus 18 (2005) 370-373
40. Australian Government, and Department of Health and Ageing. Pharmaceutical Benefits Scheme (2007)
41. Australian Government, and Australian Institute of Health and Welfare. Australian Hospital Statistics 2001-02. http://www.aihw.gov.au/publications/index.cfm/title/8881 Accessed March 12, 2009
42. Therapeutic Guidelines: Gastrointestinal Writing Group. Therapeutic Guidelines: Gastrointestinal. 3rd ed. (2002), Therapeutic Guidelines Ltd, Melbourne, Australia
43. Inadomi J.M., McIntyre L., Bernard L., and Fendrick A.M. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): A prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs. Am J Gastroenterol 98 (2003) 1940-1944
44. Therapeutic Guidelines: Analgesic Writing Group. Therapeutic Guidelines: Analgesic. 4th ed. (2002), Therapeutic Guidelines Ltd, Melbourne, Australia
45. Girvin B., Rafferty T., Stevenson M., and Johnston G.D. Uptake of COX-2 selective inhibitors and influence on NSAID prescribing in Northern Ireland. Pharmacoepidemiol Drug Saf 13 (2004) 153-157
46. National Agency for Medicines [Finland]. Drug consumption statistics (2007). http://www.nam.fi/english/medicines/drug_consumption/index.html Accessed October 24, 2007
47. Jackson S.H., Mangoni A.A., and Batty G.M. Optimization of drug prescribing. Br J Clin Pharmacol 57 (2004) 231-236
48. McManus P., Marley J., Birkett D.J., and Lindner J. Compliance with restrictions on the subsidized use of proton pump inhibitors in Australia. Br J Clin Pharmacol 46 (1998) 409-411
49. Parliament of Australia, Parliamentary Library, and Rickard M. The pharmaceutical benefits scheme: Options for cost control. Current Issues Brief no. 12, 2001-02. http://www.aph.gov.au/library/Pubs/CIB/2001-02/02cib12.htm Accessed March 12, 2009
50. Agenzia Italiana del Farmaco. Prontuario Farmaceutico Nazionale 2005. http://www.agenziafarmaco.it/ATTIVITA_EDITORIALE/section8bd4.html?target =&area_tematica=ATTIVITA_EDITORIALE%C2%A7ion_code=AIFA_PUB_PFN&e ntity_id=111.19977.1133834662520 Accessed March 12, 2009
51. PharmaCare. BC PharmaCare News-letter 05 (2005) 1-3
52. Nova Scotia Department of Community Services. Proton pump inhibitors-policy changes. May Bulletin 2003.
53. National Prescribing Service. GORD and non-ulcer dyspepsia-symptoms and risk factors. NPS News (2001), National Prescribing Service Limited, Sydney 14. http://www.nps.org.au/__data/assets/pdf_file/0005/15782/news14.pdf 2001. Accessed March 12, 2009
54. National Prescribing Service Limited (NPS). NPS News 46: Proton pump inhibitors [NPS Web site]. http://www.nps.org.au/health_professionals/publications/nps_news/current /nps_news_46/proton_pump_inhibitors Accessed March 12, 2009
55. Australian Government, and Department of Health and Ageing. Australian Statistics on Medicines 2003. http://www.health.gov.au/internet/main/Publishing.nsf/Content/872454E0BD D67CA5CA257110000A95FD/$File/Stats%20on%20Medicines.pdf Accessed March 12, 2009
56. Australian Government, and Department of Health and Ageing. Australian Statistics on Medicines 2001-2002. http://www.health.gov.au/internet/main/Publishing.nsf/Content/health-pbs -general-pubs-asm.htm/$FILE/asm01.pdf Accessed March 12, 2009
57. Australian Government, Department of Health and Ageing, and Pharmaceutical Pricing Section Pharmaceutical Benefits Branch. Expenditure and prescriptions: Twelve months to 31 December 2003. http://www.health.gov.au/internet/main/Publishing.nsf/Content/3CC2D4DF82 1FE5ADCA2570F40005B9B1/$File/pb-dec03.pdf Accessed March 12, 2009
58. Australian Government, and Department of Health and Ageing. PBS pricing. Administrative guideline on the scope of the 12.5% price reduction policy (Updated July 2005). http://www.health.gov.au/internet/main/publishing.nsf/Content/health-pbs -pricing-adminguide Accessed March 12, 2009
59. Cooke C., Nissen L., Sketris I., and Tett S.E. Quantifying the use of the statin antilipemic drugs: Comparisons and contrasts between Nova Scotia, Canada, and Queensland, Australia. Clin Ther 27 (2005) 497-508
60. Tett S.E., Smith A.J., Sketris I., et al. A comparison of benzodiazepine and related drug use in Nova Scotia, Canada and Australia. Abstract 108. Presented at: 4th Canadian Therapeutics Congress. Halifax, Nova Scotia (May 27-30, 2007). http://www.cjcp.ca/pdf/4thcongress_F_may11correct.pdf Accessed March 12, 2009
61. McManus P., Primrose J.G., Henry D.A., et al. Pattern of non-steroidal anti-inflammatory drug use in Australia 1990-1994. A report from the Drug Utilization Sub-Committee of the Pharmaceutical Benefits Advisory Committee. Med J Aust 164 (1996) 589-592
62. Strom B. Pharmacoepidemiology. 4th ed. (2005), John Wiley & Sons, Bognor Regis, United Kingdom